Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Childhood absence epilepsy (CAE), also known as pyknolepsy, is an idiopathic generalized epilepsy which occurs in otherwise normal children. The age of onset is between 4–10 years with peak age between 5–7 years. Children have absence seizures which although brief (~4–20 seconds), they occur frequently, sometimes in the hundreds per day. The absence seizures of CAE involve abrupt and severe impairment of consciousness. Mild automatisms are frequent, but major motor involvement early in the course excludes this diagnosis. The EEG demonstrates characteristic "typical 3Hz spike-wave" discharges. Prognosis is excellent in well-defined cases of CAE with most patients "growing out" of their epilepsy.
The report details the trend, potential and market size of Childhood Absence Epilepsy Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Childhood Absence Epilepsy Treatmentmarket, defines the market attractiveness level of Childhood Absence Epilepsy Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Childhood Absence Epilepsy Treatment industry, describes the types of Childhood Absence Epilepsy Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Childhood Absence Epilepsy Treatment market and the development prospects and opportunities of Childhood Absence Epilepsy Treatment industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Childhood Absence Epilepsy Treatment market in Chapter 13.
By Player:
Teva Pharmaceutical
Pfizer
AbbVie
Insys Therapeutics
GlaxoSmithKline
Cavion Inc
By Type:
Ethosuximide
Valproate
Lamotrigine
CX-8998
Cannabidiol Oral Solution
By End-User:
Typical Absence Seizures
Atypical Absence Seizures
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Childhood Absence Epilepsy Treatment Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Childhood Absence Epilepsy Treatment Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Childhood Absence Epilepsy Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Childhood Absence Epilepsy Treatment Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Childhood Absence Epilepsy Treatment Market Analysis and Outlook to 2022
-
7.1 Global Childhood Absence Epilepsy Treatment Consumption (2017-2022)
-
7.2 United States Childhood Absence Epilepsy Treatment Consumption (2017-2022)
-
7.3 Europe Childhood Absence Epilepsy Treatment Consumption (2017-2022)
-
7.4 China Childhood Absence Epilepsy Treatment Consumption (2017-2022)
-
7.5 Japan Childhood Absence Epilepsy Treatment Consumption (2017-2022)
-
7.6 India Childhood Absence Epilepsy Treatment Consumption (2017-2022)
-
7.7 South Korea Childhood Absence Epilepsy Treatment Consumption (2017-2022)
8 Region and Country-wise Childhood Absence Epilepsy Treatment Market Analysis and Outlook to 2028
-
8.1 Global Childhood Absence Epilepsy Treatment Consumption Forecast (2022-2028)
-
8.2 United States Childhood Absence Epilepsy Treatment Consumption Forecast (2022-2028)
-
8.3 Europe Childhood Absence Epilepsy Treatment Consumption Forecast (2022-2028)
-
8.4 China Childhood Absence Epilepsy Treatment Consumption Forecast (2022-2028)
-
8.5 Japan Childhood Absence Epilepsy Treatment Consumption Forecast (2022-2028)
-
8.6 India Childhood Absence Epilepsy Treatment Consumption Forecast (2022-2028)
-
8.7 South Korea Childhood Absence Epilepsy Treatment Consumption Forecast (2022-2028)
9 Global Childhood Absence Epilepsy Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global Childhood Absence Epilepsy Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Ethosuximide Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Valproate Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Lamotrigine Consumption and Growth Rate (2017-2022)
-
9.1.4 Global CX-8998 Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Cannabidiol Oral Solution Consumption and Growth Rate (2017-2022)
-
9.2 Global Childhood Absence Epilepsy Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Typical Absence Seizures Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Atypical Absence Seizures Consumption and Growth Rate (2017-2022)
10 Global Childhood Absence Epilepsy Treatment Market Outlook by Types and Applications to 2028
-
10.1 Global Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Ethosuximide Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Valproate Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Lamotrigine Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global CX-8998 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Cannabidiol Oral Solution Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Typical Absence Seizures Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Atypical Absence Seizures Consumption Forecast and Growth Rate (2022-2028)
11 Global Childhood Absence Epilepsy Treatment Import and Export Analysis (Top 5 Countries)
-
11.1 Global Childhood Absence Epilepsy Treatment Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Childhood Absence Epilepsy Treatment Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Childhood Absence Epilepsy Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Childhood Absence Epilepsy Treatment Market Competitive Analysis
-
14.1 Teva Pharmaceutical
-
14.1.1 Teva Pharmaceutical Company Details
-
14.1.2 Teva Pharmaceutical Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Teva Pharmaceutical Childhood Absence Epilepsy Treatment Product and Service
-
14.2 Pfizer
-
14.2.1 Pfizer Company Details
-
14.2.2 Pfizer Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Pfizer Childhood Absence Epilepsy Treatment Product and Service
-
14.3 AbbVie
-
14.3.1 AbbVie Company Details
-
14.3.2 AbbVie Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 AbbVie Childhood Absence Epilepsy Treatment Product and Service
-
14.4 Insys Therapeutics
-
14.4.1 Insys Therapeutics Company Details
-
14.4.2 Insys Therapeutics Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Insys Therapeutics Childhood Absence Epilepsy Treatment Product and Service
-
14.5 GlaxoSmithKline
-
14.5.1 GlaxoSmithKline Company Details
-
14.5.2 GlaxoSmithKline Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 GlaxoSmithKline Childhood Absence Epilepsy Treatment Product and Service
-
14.6 Cavion Inc
-
14.6.1 Cavion Inc Company Details
-
14.6.2 Cavion Inc Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Cavion Inc Childhood Absence Epilepsy Treatment Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Childhood Absence Epilepsy Treatment
-
Figure Childhood Absence Epilepsy Treatment Picture
-
Table Global Childhood Absence Epilepsy Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Childhood Absence Epilepsy Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Childhood Absence Epilepsy Treatment Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Childhood Absence Epilepsy Treatment Consumption by Country (2017-2022)
-
Figure United States Childhood Absence Epilepsy Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe Childhood Absence Epilepsy Treatment Consumption and Growth Rate (2017-2022)
-
Figure China Childhood Absence Epilepsy Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan Childhood Absence Epilepsy Treatment Consumption and Growth Rate (2017-2022)
-
Figure India Childhood Absence Epilepsy Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea Childhood Absence Epilepsy Treatment Consumption and Growth Rate (2017-2022)
-
Figure Global Childhood Absence Epilepsy Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Childhood Absence Epilepsy Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ethosuximide Consumption and Growth Rate (2017-2022)
-
Figure Global Valproate Consumption and Growth Rate (2017-2022)
-
Figure Global Lamotrigine Consumption and Growth Rate (2017-2022)
-
Figure Global CX-8998 Consumption and Growth Rate (2017-2022)
-
Figure Global Cannabidiol Oral Solution Consumption and Growth Rate (2017-2022)
-
Figure Global Typical Absence Seizures Consumption and Growth Rate (2017-2022)
-
Figure Global Atypical Absence Seizures Consumption and Growth Rate (2017-2022)
-
Figure Global Ethosuximide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Valproate Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lamotrigine Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global CX-8998 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Cannabidiol Oral Solution Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Typical Absence Seizures Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Atypical Absence Seizures Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Childhood Absence Epilepsy Treatment Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Childhood Absence Epilepsy Treatment Export by Region (Top 5 Countries) (2017-2028)
-
Table Teva Pharmaceutical (Foundation Year, Company Profile and etc.)
-
Table Teva Pharmaceutical Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Childhood Absence Epilepsy Treatment Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Childhood Absence Epilepsy Treatment Product and Service
-
Table AbbVie (Foundation Year, Company Profile and etc.)
-
Table AbbVie Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Childhood Absence Epilepsy Treatment Product and Service
-
Table Insys Therapeutics (Foundation Year, Company Profile and etc.)
-
Table Insys Therapeutics Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Insys Therapeutics Childhood Absence Epilepsy Treatment Product and Service
-
Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Childhood Absence Epilepsy Treatment Product and Service
-
Table Cavion Inc (Foundation Year, Company Profile and etc.)
-
Table Cavion Inc Childhood Absence Epilepsy Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cavion Inc Childhood Absence Epilepsy Treatment Product and Service
-
